Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Proof-of-concept study of tasimelteon in travelers with jet lag disorder
2016-002213-21Phase 2Terminated
- Sponsor
- Vanda Pharmaceuticals Inc.
- Start
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in jet lag disorder comparing Tasimelteon 20 mg with Placebo (2 arms). Primary endpoint: Nighttime sleep parameters by polysomnography after transmeridian travel. Started Jun 2016; status: terminated.
02
Drugs
tasimelteon
03
Conditions
jet lag disorder
Beyond the preview
Go deeper on 2016-002213-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002213-21.